Vasopressors in sepsis: Do they change the outcome?

Marco A. González, Cristhiaan D. Ochoa

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The final event in septic shock is multiorgan failure syndrome as a consequence of hypoperfusion resulting from a late, refractory vasodilatory shock. Before starting vasoactive agents, the underlying infectious disease must be under treatment, the volume status aggressively corrected, the immunomodulatory therapy started, and adrenal gland failure ruled out. NE is the vasoactive agent with the best results in refractory shock, and it is probably the vasoconstrictor that most improves mortality in septic patients. VP levels are depleted in the late phase of septic shock. If the patient is hypotensive, even though vasoactive agents and inotropes are used, VP should be started at low doses.

Original languageEnglish (US)
Title of host publicationSepsis (Second Edition)
PublisherSpringer New York
Pages121-125
Number of pages5
ISBN (Print)0387298169, 9780387298160
DOIs
StatePublished - Dec 1 2006

    Fingerprint

ASJC Scopus subject areas

  • Medicine(all)

Cite this

González, M. A., & Ochoa, C. D. (2006). Vasopressors in sepsis: Do they change the outcome? In Sepsis (Second Edition) (pp. 121-125). Springer New York. https://doi.org/10.1007/0-387-34574-4_10